Legend Biotech Stock News

Legend Biotech Corporation's (NASDAQ: LEGN) collaborating partner Janssen Pharmaceutical has submitted a marketing application to the Japanese Ministry of Health, Labour and Welfare (MHLW) seekin

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech Corporation (NASDAQ: LEGN), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) for ciltacabtagene autoleucel (cilta-cel) by its collaboration partner, Janssen Pharmaceutical K.K. (Janssen). Cilta-cel is an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen rec

Legend Biotech (NASDAQ:LEGN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. […]

Legend Biotech (NASDAQ:LEGN) announced its quarterly earnings data on Monday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts consensus estimates of ($0.35) by ($0.08), MarketWatch Earnings reports. Legend Biotech had a negative net margin of 343.40% and a negative return on equity of 101.68%. NASDAQ:LEGN traded up $3.30 during mid-day []

Related Stocks: PACB , BYND , NTLA , NRIX , NSTG , LSPD , DSGX , LEGN , RKLB , BRKR , ASTR , ACAD , SRAC , MCRB ,

Biopharmaceutical company Legend BioTech (LEGN) hit a new 54-week high this Tuesday, up 103.4% this year.  LEGN is a multinational biopharmaceutical company primarily engaged in the discovery and dev

Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021.

A recent regulatory overhaul designed to speed up development and approval of new drugs in China has been welcomed by global pharma giants and local startups alike, aimed at bringing their latest cutt

Legend Biotech (LEGN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

The stock price of Legend Biotech Corp (NASDAQ: LEGN) increased by over 7% pre-market. This is why it happened.

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN #CARTcell--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and developm

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel c

Investors need to pay close attention to Legend Biotech (LEGN) stock based on the movements in the options market lately.

The stock price of Legend Biotech Corp (NASDAQ: LEGN) increased by over 10% during intraday trading. This is why it happened.